Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ehjcvp/pvy043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dynamic Data-Driven Management of Atrial Fibrillation With Implantable Cardiac Monitors: The MONITOR AF Study.
Heart Rhythm
January 2025
Kansas City Hearth Rhythm Institute, Overland Park, KS. Electronic address:
Background: Implantable cardiac monitors (ICMs) provide valuable insights into managing atrial fibrillation (AF). Data suggest that ICMs increase AF detection, but their impact on management is still uncertain.
Objectives: To evaluate and compare the impact of ICMs on the clinical management of AF.
26-Week Repeated-Dose Toxicity Study of a Novel Antiarrhythmic Drug Sulcardine Sulfate in Sprague-Dawley Rats.
J Appl Toxicol
January 2025
School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China.
Sulcardine sulfate (Sul) is a novel antiarrhythmic agent blocking multiple channels and exhibits unique pharmacological properties such as lower APD-dependent prolongation and reduced arrhythmia risk. Sul is currently in Phase III clinical trials, yet studies on its long-term toxicological profile and potential target organs remain unexplored. This study investigated the related toxicity of Sul in Sprague Dawley (SD) rats through repeated oral administration for 26 weeks, followed by a 4-week recovery period.
View Article and Find Full Text PDFBackground: Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium-term efficacy and safety, while long-term outcomes are unknown.
Methods And Results: A total of 92 consecutive patients with symptomatic obstructive HCM with peak left ventricular outflow tract gradients of ≥30 mm Hg at rest or with provocation who were maintained on disopyramide for ≥5 years at 2 dedicated HCM centers were included: 92 patients; mean age, 62.5 years; 54% women; treated with disopyramide for median 7.
Rhythm Control Better Prevents Stroke than Rate Control in Patients with Concomitant Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Nationwide Population Based Cohort Study with Long-Term Follow-Up.
Acta Cardiol Sin
January 2025
Cardiovascular Center, Taichung Veterans General Hospital, Taichung.
Background: Atrial fibrillation (AF) increases the risks of stroke and mortality. It remains unclear whether rhythm control reduces the risk of stroke in patients with AF concomitant with hypertrophic cardiomyopathy (HCM).
Methods: We identified AF patients with HCM who were ≥ 18 years old in the Taiwan National Health Insurance Database.
Clinical Profile and Management of Wolf-Parkinson White Syndrome and Asymptomatic Pre-Excitation Carriers in Africa: A Multicenter Pan African Registry From 17 Countries.
J Cardiovasc Electrophysiol
January 2025
Douala Gyneco-obstetric and Pediatric Hospital/University of Douala, Douala, Cameroon.
Article Synopsis
- The study explores the management and diagnosis of Wolf-Parkinson White Syndrome (WPW) and asymptomatic pre-excitation in Africa, highlighting a lack of data in the region.
- Conducted in 20 centers across 17 African countries, the research involved 541 participants and focused on symptomatology, treatment approaches, and the impact of local health dynamics on care.
- Results indicated that a vast majority were diagnosed with WPW, with significant regional differences in treatment options and effectiveness, showing that Northern and Southern Africa have more advanced practices compared to other areas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!